Mission: The Consortium on Translational Research in the Microbiome (CTRM) is a community of practice focused on facilitating the implementation of microbiome research to enhance drug discovery and development. By focusing upon harmonization of emerging enabling technologies, we provide a collaborative platform for knowledge sharing and consensus building.
Background: Over the past decade, the human microbiome as an avenue for new drug discovery and development has gained significant attention from academics, industry professionals, funding agencies and investors. However, much of the data to date has only provided correlative evidence of clinical applications, leaving many technical challenges and unknowns.
To realize the potential of this growing body of evidence from the human microbiome, the biopharma community must address the factors limiting translation of these expanding, fascinating, results into novel diagnostics and effective therapeutics. The challenges of today’s wild wild west environment for enabling technologies resonated as a smart and important focus for our efforts.
Through literature review and discussion with practitioners and suppliers, we have chosen to target challenges to the progress of enabling technologies. Our intention is to build a community of practice focused upon accelerating the development of standards in translational microbiome research while respecting the complexities of harmonization.
Who We Are: The CTRM was established in 2017 through mutual interests in the human microbiome and the professional connections of the Institute for Life Science Entrepreneurship at Kean University in New Jersey, the Office of Research at the City University of New York and the Westchester Biotech Project.
Each individual on the committee, and the organizations they represent, appreciate the clinical potential of research on the human microbiome. And, each wants to work collaboratively in the development of enabling technologies and know-how, as a basis for the translation of scientific findings into effective medical breakthroughs.
Finally, all of us are dedicated to accelerating the discovery and development of new treatments to ensure better health and address unmet needs
Keith Bostian, Ph.D., CEO, Institute for Life Science Entrepreneurship
Eric Vieira, Ph.D., Director, Special Research Programs, City University of New York
Raul Cano, Ph.D., Chief Scientific Officer, The BioCollective, and Advisor Institute for Life Science Entrepreneurship
Joan Bennett, Ph.D., Distinguished Professor, School of Environmental and Biological Sciences, Rutgers University
Scott A. Jackson, Ph.D., Leader – Complex Microbial Systems Group, Biosystems and Biomaterials Division, NIST
Sam Kongsamut, Ph.D., Executive Director, Institute for Life Science Entrepreneurship
Dev Mittar, Ph.D., Lead Scientist, Microbiology R&D, ATCC
Tasha Santiago-Rodriguez, Ph.D., Microbiome Discovery Analyst, Diversigen
Howard Young, Ph.D., Senior Investigator, Cancer and Inflammation Program, NIH, National Cancer Institute/CCR
Joanne Gere, Executive Director, Westchester Biotech Project
Christopher Kinzel, Associate for Communication, Westchester Biotech Project